We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Justice Department Vows to Keep Spotlight on Off-Label Rx Fraud
Justice Department Vows to Keep Spotlight on Off-Label Rx Fraud
September 20, 2005
Ferreting out off-label drug fraud remains a top priority at the Department of Justice (DOJ), especially in light of the government’s aim to cut $10 billion from Medicaid and the new competitive pressures expected with next year’s Medicare prescription drug benefit, says a top DOJ official.